Speakers

John Allan, Danielle Brander, Matthew Davids, Brian Hill, Loretta Nastoupil, Javier Pinilla-Ibarz, Kerry Rogers, Stephen Spurgeon, Nina Wagner-Johnston, Jennifer Woyach

John Allan, MD

Assistant Professor of Medicine
Division of Hematology and Medical Oncology
Weill Cornell Medicine
New York, New York

Dr. Allan is an Assistant Professor of Medicine in the Division of Hematology and Medical Oncology at Weill Cornell Medicine in New York, New York. He received a Bachelor of Science in both Biochemistry and Finance at the University of Missouri in Columbia, Missouri, and completed his medical degree at Saint Louis University School of Medicine in St. Louis, Missouri. Seeking an internal medicine residency program with a particular strength in oncology, Dr. Allan moved to New York to train at New York–Presbyterian Hospital, Weill Cornell Medical Campus, where he also completed his hematology and medical oncology fellowship.

Dr. Allan joined the lymphoma faculty in the Division of Hematology and Oncology upon completion of his training, and he is a member of the Chronic Lymphocytic Leukemia (CLL) Research Center at Weill Cornell Medicine. He treats all lymphoid malignancies and has particular interest in improving therapies for patients with CLL and Richter’s Syndrome, which is the focus of his research.

Back to top

Danielle Brander, MD

Assistant Professor of Medicine
Department of Medicine
Duke University School of Medicine
Durham, NC

Dr. Brander completed her medical degree, internal medicine residency, and hematology and oncology fellowship at Duke University, and is Assistant Professor of Medicine in the Division of Hematologic Malignancies and Cellular Therapy at the Duke Cancer Institute in Durham, North Carolina. She leads the Duke Chronic Lymphocytic Leukemia (CLL) and Indolent Lymphoma Clinic, serving as site primary investigator for CLL-focused clinical trials, many in collaboration with other academic CLL research centers.

Dr. Brander has participated nationally in both the American Society of Hematology (ASH) Clinical Research Training Program and the Lymphoma Research Foundation (LRF) Lymphoma Clinical Research Mentoring Program, and she hopes to continue to bring novel treatment approaches for her patients. She is Team Lead for the Duke Lymphoma Clinical Research Working Group and the Duke B-cells Behaving Badly Research Working Group, and is dedicated to institutional and national educational initiatives through her participation in the Leukemia and Lymphoma Society (LLS), Lymphoma Research Foundation (LRF), and the CLL Society.

Dr. Brander also continues her work in the laboratory with other members of the Duke CLL Research Team to study biomarkers of CLL that could aid in predicting treatment-related toxicity and resistance and serve as future therapeutic targets. She has been honored for her research and teaching, including the Silber Award for Most Outstanding Research, the Elizabethtown College Apgar Distinguished Alumni Award, and the William Kane Hematology/Oncology Junior Faculty Teaching Award.

Back to top

Matthew Davids, MD, MMSc

Assistant Professor of Medicine
Harvard Medical School
Director, Lymphoma BioBank
Associate Director, CLL Center
Dana-Farber Cancer Institute
Boston, MA

Dr. Davids is an Assistant Professor of Medicine at Harvard Medical School (HMS), Attending Physician in the Division of Hematologic Malignancies at Dana-Farber Cancer Institute (DFCI), Associate Director of the DFCI Chronic Lymphocytic Leukemia (CLL) Center, and Director of the DFCI Lymphoma BioBank in Boston, Massachusetts. After obtaining a Bachelor of Arts in Chemistry at Harvard College, Dr. Davids completed his medical degree at Yale University School of Medicine in New Haven, Connecticut. He served as an intern, resident, and Assistant Chief Resident in internal medicine at New York–Presbyterian Weill Cornell Medical Center and Memorial Sloan-Kettering Cancer Center in New York, New York. He completed his fellowship in hematology and oncology in Dana-Farber/Partners CancerCare, and a Master of Medical Science (MMSc) at Harvard Medical School.

Dr. Davids has an active translational research program in chronic CLL, studying B-cell lymphoma (Bcl)-2 biology in his laboratory, and leading clinical trials to evaluate novel therapeutic strategies in patients with CLL and other hematologic malignancies. His work focuses on the Bcl-2 inhibitor venetoclax, novel combinations of B-cell receptor pathway inhibitors, and checkpoint blockade to enhance anti-tumor immunity in patients with hematologic malignancies who relapse post–allogeneic hematopoietic cell transplantation.

Back to top

Brian Hill, MD, PhD

Director, Lymphoid Malignancies Program
Staff Physician, Department of Hematology and Medical Oncology
Taussig Cancer Institute
Assistant Professor, Cleveland Clinic Lerner College of Medicine
Cleveland Clinic
Cleveland, OH

Dr. Hill is an Assistant Professor of Medicine at the Cleveland Clinic Lerner College of Medicine at Case Western Reserve University in Cleveland, Ohio. He received his undergraduate degree from Dartmouth College and earned his PhD in genetics through work done at Cold Spring Harbor Laboratory in Cold Spring Harbor, New York. Dr. Hill received his medical degree and completed his residency in internal medicine at the University of Chicago Pritzker School of Medicine. He completed his fellowship in hematology and oncology at the Cleveland Clinic. Dr. Hill currently is the Director of the Lymphoid Malignancies Program and a staff physician in the Cleveland Clinic Taussig Cancer Institute. His clinical and research focus is in chronic lymphocytic leukemia (CLL) and lymphoma. He also is the principal investigator of multiple on-going clinical trials of new cancer treatments, including novel cellular therapies.

Back to top

Loretta Nastoupil, MD

Assistant Professor
Department of Lymphoma/Myeloma
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

Dr. Nastoupil completed her undergraduate degree at Texas Tech Health Sciences Center in Lubbock, Texas, graduating summa cum laude in 2003. She obtained her medical degree from the University of Texas Southwestern Medical School at Dallas in 2007; then she completed an internship and internal medicine residency at Washington University, Barnes-Jewish Hospital in St. Louis, Missouri. Following residency, Dr. Nastoupil completed a hematology-medical oncology fellowship at Emory University in Atlanta, Georgia, serving as chief fellow her last year.

Dr. Nastoupil joined the faculty at MD Anderson Cancer Center in Houston, Texas, in 2013 as an assistant professor in the Department of Lymphoma/Myeloma. She is a clinical researcher with a focus on lymphoma epidemiology and outcomes. The goal of her research is to identify risk factors associated with lymphoma and eliminate disparities in outcomes to improve survival for all patients with lymphoma. She is actively involved in early phase drug development, as well as immune therapy studies in indolent lymphoma. She also is exploring predictive biomarkers with modern therapy in lymphoma.

Back to top

Javier Pinilla-Ibarz, MD, PhD

Lymphoma Section Head
Director of Immunotherapy
Malignant Hematology Department
H. Lee Moffitt Cancer Center & Research Institute
Tampa, FL

Dr. Pinilla-Ibarz is a Professor in the Department of Oncologic Sciences in the College of Medicine at the University of South Florida in Tampa, Florida. He also is a senior member, the Head of the Lymphoma Section, and the Director of Immunotherapy in the Department of Malignant Hematology at the Moffitt Cancer Center. Dr. Pinilla-Ibarz received both his medical degree and doctorate from the University of Zaragoza School of Medicine in Zaragoza, Spain. He completed his residency in medicine and a fellowship in hematology at La Paz University Hospital in Madrid, Spain; and after moving to the United States, he also completed a residency in internal medicine at Cornell Medical Center and a fellowship in hematology/oncology at the Memorial Sloan Kettering Cancer Center in New York, New York.

Dr. Pinilla-Ibarz has led the chronic leukemia program at Moffitt since 2006; and the program’s principal interests in the clinic focus on patients with myeloid and lymphoid chronic leukemia. In this regard, Dr. Pinilla-Ibarz has participated in multiple clinical trials involving tyrosine kinase inhibitors, some of which are now FDA approved.

As Director of Immunotherapy for Malignant Hematology, Dr. Pinilla-Ibarz has been involved in the development of new immunotherapeutic approaches in malignant hematology. He has participated in several clinical trials of peptide and cellular vaccines in various hematological disorders. His laboratory is interested in epigenetic immunoregulation in lymphoid and myeloid leukemias. Other research areas of focus include the role of the bone marrow microenvironment in mediating resistance to TKis and the interaction of TKis with the immune system. Dr. Pinilla-Ibarz frequently presents his findings at annual meetings of the American Hematology Association and the American Society of Clinical Oncology, and at other national and international meetings. His work has been published in journals including Blood, Nature Immunology, and Seminars of Hematology and Leukemia. He also has authored multiple book chapters.

Back to top

Kerry Rogers, MD

Assistant Professor
Division of Hematology
Department of Internal Medicine
The Ohio State University
Columbus, OH

Dr. Rogers is an Assistant Professor in the Division of Hematology at The Ohio State University (OSU) in Columbus, Ohio, and specializes in Chronic Lymphocytic Leukemia (CLL) and Hairy Cell Leukemia (HCL). She earned a bachelor’s degree from Northwestern University in Evanston, Illinois, and a medical degree from the Chicago Medical School in North Chicago, Illinois. Dr. Rogers completed her residency in internal medicine at University of Michigan in Ann Arbor, Michigan, and a fellowship in hematology and medical oncology at OSU, where she currently is a faculty member. She is board certified in Internal Medicine, Hematology, and Medical Oncology. In addition to caring for patients with CLL and HCL in clinic, Dr. Rogers is the principal investigator on several clinical trials studying chemotherapy-free combination regimens for CLL using currently approved or novel agents. The group at OSU has lead the development of ibrutinib, as well as other Bruton’s tyrosine kinase (BTK) inhibitors, and pioneered research into its effects on the immune environment and molecular mechanisms of resistance. Dr. Rogers also is part of the active HCL research group at OSU. Her other clinical research interests include complications of targeted therapy for CLL, management of Richter’s syndrome, and CLL-associated autoimmune cytopenias. Additionally, she conducts laboratory research in autoimmune hemolytic anemia.

Back to top

Stephen Spurgeon, MD

Associate Professor of Medicine
Division of Hematology and Medical Oncology
Section Head, Hematologic Malignancies
Knight Cancer Institute
Oregon Health & Science University
Portland, OR

Dr. Spurgeon received his medical degree from Jefferson Medical College (now Sidney Kimmel Medical College) at Thomas Jefferson University in Philadelphia, Pennsylvania. He continued his training in internal medicine at Oregon Health & Science University (OHSU) in Portland, Oregon, where he also served as Chief Resident. Subsequently, he completed a fellowship in hematology and medical oncology at OHSU. Dr. Spurgeon joined the OHSU faculty at the Center for Hematologic Malignancies (CHM) in the Knight Cancer Institute (KCI) in July 2009 as an assistant professor. He currently is an associate professor and serves as the Section Head of Hematologic Malignancies. He continues to specialize in the care of patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma at CHM and at the KCI East Portland Office. He collaborates with a number of colleagues at the KCI to better define therapeutic targets and develop targeted therapies across a number of blood cancers.

Back to top

Nina Wagner-Johnston, MD

Associate Professor of Oncology
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, MD

Dr. Wagner-Johnston is an Associate Professor of Oncology at Johns Hopkins University in Baltimore, Maryland. She received her Bachelor of Science in Nursing from Georgetown University in Washington, DC, and after five-years as a bone marrow transplant research nurse, she decided to pursue medicine. Dr. Wagner-Johnston attended medical school at the University of Chicago in Chicago, Illinois, and remained there for her residency training. Maintaining her interest in hematologic malignancies, she pursued a fellowship in medical oncology at Johns Hopkins with a basic and clinical research focus in lymphoma. She joined the medical oncology faculty at Washington University in St. Louis, Missouri, in 2008 and was recruited back to Johns Hopkins in 2015. She serves as the Co-Director of Clinical Research Operations for Hematologic Malignancies and the Director of Lymphoma Drug Development. Her research interests focus on targeted therapies for patients with non-Hodgkin lymphoma.

Back to top

Jennifer Woyach, MD

Associate Professor of Medicine
Division of Hematology
Department of Internal Medicine
The Ohio State University
Columbus, OH

Dr. Woyach is an Associate Professor in the Division of Hematology at The Ohio State University (OSU) in Columbus, Ohio, with a focus on translational research in chronic lymphocytic leukemia (CLL). Though the majority of her time is dedicated to research, which includes laboratory and clinical investigation, she also is the clinical leader of the CLL group at OSU.

Dr. Woyach is principal investigator for multiple early stage clinical trials investigating novel targeted therapies for CLL and other hematologic malignancies, and mentors junior faculty members in the development and conduct of Phase I studies. She is chair of the intergroup Phase III study A041202, which investigates chemoimmunotherapy versus targeted therapy as initial treatment for older adults with CLL.

Dr. Woyach’s laboratory interests include experimental therapeutics in CLL with a current focus on signaling pathways and kinase inhibition. Most of her work has focused on BTK inhibitors, resistance mechanisms associated with BTK inhibitors, and strategies to overcome resistance. Additionally, Dr. Woyach leads preclinical and clinical endeavors to identify risk factors for the development of resistance to BTK inhibitors and to explore novel pathways to prevent or circumvent resistance.

Back to top